BioSpace News Archive

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Health Insurance Innovations, Inc. of the April 22, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Syneos Health, Inc. resulting from allegations that Syneos and/or its executives may have issued materially misleading business information to the investing public.

Peli BioThermal, the global name in temperature controlled packaging, announces the opening of a new network station and service centre in Dublin, Ireland to service, refurbish, repair and condition Peli BioThermal’s reusable Crēdo on Demand shippers.

Perrigo Company plc announced financial results for the fourth quarter and calendar year ended December 31, 2018.

MTS Systems Corporation, a leading global supplier of high-performance test systems, motion simulators and sensors, announced the use of MTS material test systems to develop 3D-printed, porous titanium spinal implants.

REGENXBIO Inc. announced financial results for the fourth quarter and full year ended December 31, 2018, and recent operational highlights.

The journal Scientific Reports has published today the results of a research study looking at the contribution of genetic variants, family history and obesity to the development of type 2 diabetes.

Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) to commence human pharmacokinetics studies for the Company’s lead asset NXP001.

NJ accelerator announces agreement with CARB-X Global Accelerator Network

CAC Corporation (Head Office: Chuo-ku, Tokyo; President and CEO: Ryota Nishimori; hereinafter called “CAC”) has signed a partnership agreement with rfxcel Corporation (Head Office: Reno, Nevada, USA; CEO: Glenn Abood; hereinafter called “rfxcel”) in the pharmaceutical traceability field.